Dengue - Sample Collection Study Pakistan

NCT ID: NCT07203183

Last Updated: 2025-10-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-10-01

Study Completion Date

2026-04-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study is to collect well-characterized serum and plasma specimens from confirmed dengue positive and dengue negative subjects to support dengue diagnostic products development.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dengue

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

dengue positives

No interventions assigned to this group

dengue negatives

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥12-years-old
* Individuals suspected or confirmed for active dengue, with dengue-consistent symptoms onset up to and including 10 days before enrolment in this trial.

Exclusion Criteria

* Subject has been vaccinated for dengue.
* Subject participates in an investigative drug, vaccine or medical device clinical study
* Participant is deemed unfit for the study by the Investigator
* Participant is unwilling or unable to provide informed consent
Minimum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Aga Khan University

OTHER

Sponsor Role collaborator

National University of Medical Sciences, Pakistan

OTHER

Sponsor Role collaborator

Abbott Rapid Dx

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Simon Kordowich, PHD

Role: CONTACT

+353 (0)91 429 900

Jocelyn Farge, MSc, MBA

Role: CONTACT

+353 (0)91 429 900

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SDRD-K-029-P

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

COVID-19 Immunity Assessment
NCT05080231 COMPLETED
Blood Testing at Entia
NCT05580055 UNKNOWN